A randomized, double-blind, two arm, parallel, placebo controlled study of rimonabant 20 mg effect on high density lipoprotein kinetics in patients with abdominal obesity and additional cardiometabolic risk factors.
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2012
At a glance
- Drugs Rimonabant (Primary)
- Indications Dyslipidaemias; Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 12 Jan 2009 Actual patient numbers added (n=64), as reported by Clinicaltrials.gov
- 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.